A Phase II/III Study of the Safety and Efficacy of NC-503 in Patients Suffering From Secondary (AA) Amyloidosis

Trial Profile

A Phase II/III Study of the Safety and Efficacy of NC-503 in Patients Suffering From Secondary (AA) Amyloidosis

Completed
Phase of Trial: Phase II/III

Latest Information Update: 21 Jan 2016

At a glance

  • Drugs Eprodisate (Primary)
  • Indications Amyloid A amyloidosis
  • Focus Adverse reactions; Therapeutic Use
  • Sponsors BELLUS Health
  • Most Recent Events

    • 21 Jan 2016 According to Auven Therapeutics media release, company is planning to announce top-line results during the second quarter of 2016.
    • 21 Jan 2016 Results published in Auven Therapeutics media release.
    • 20 Jan 2014 New trial record
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top